New York S 6422: Relates to change of enrollment by previously registered voters

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 - This bill is not active in this session.

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
S06422 Summary:

BILL NOS06422 

&nbsp

SAME ASSAME AS A06927

&nbsp

SPONSORHOYLMAN-SIGAL

&nbsp

COSPNSRCOONEY

&nbsp

MLTSPNSR

&nbsp

Amd §§6807 & 6810, Ed L; add §280-d, Pub Health L

&nbsp

Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.

Go to top S06422 Actions:

BILL NOS06422 

&nbsp

03/13/2025REFERRED TO HIGHER EDUCATION

Go to topS06422 Committee&nbspVotes:

Go to topS06422 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topS06422 Text:

 STATE OF NEW YORK
 ________________________________________________________________________

 6422

 2025-2026 Regular Sessions

 IN SENATE

 March 13, 2025
 ___________

 Introduced by Sen. HOYLMAN-SIGAL -- read twice and ordered printed, and
 when printed to be committed to the Committee on Higher Education

 AN ACT to amend the education law and the public health law, in relation
 to prescription labels for mifepristone, misoprostol, gonadotropin-re-
 leasing hormone agonists, pubertal suppressants, anabolic steroids,
 alpha reductase inhibitors, progestins, or drug classes for hormone
 replacement therapy for treatment of gender dysphoria

 The People of the State of New York, represented in Senate and Assem-
 bly, do enact as follows:

 1 Section 1. Paragraph b-1 of subdivision 1 of section 6807 of the
 2 education law, as added by chapter 7 of the laws of 2025, is amended to
 3 read as follows:
 4 b-1. Notwithstanding paragraph b of this section, the prescription
 5 label for mifepristone, misoprostol, [and their generic alternatives]
 6 gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic
 7 steroids, alpha reductase inhibitors, progestins, or drug classes for
 8 hormone replacement therapy for treatment of gender dysphoria, may
 9 include the name or address of the dispensing health care practice
 10 instead of the name of the dispenser.
 11 § 2. Subdivision 1-a of section 6810 of the education law, as added by
 12 chapter 7 of the laws of 2025, is amended to read as follows:
 13 1-a. Notwithstanding subdivision one of this section, at the
 14 prescriber's request, the prescription label for mifepristone, misopros-
 15 tol, [and their generic alternatives] gonadotropin-releasing hormone
 16 agonists, pubertal suppressants, anabolic steroids, alpha reductase
 17 inhibitors, progestins, or drug classes for hormone replacement therapy
 18 for treatment of gender dysphoria, may include the name of the prescrib-
 19 ing health care practice instead of the name of the prescriber.
 20 § 3. The public health law is amended by adding a new section 280-d to
 21 read as follows:

 EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 [ ] is old law to be omitted.
 LBD10852-01-5

 S. 6422 2

 1 § 280-d. Patient notification of prescription label change. A health
 2 care prescriber shall inform the patient if such prescriber has included
 3 or has requested to include the name or address of the prescribing
 4 health care practice instead of the name of such prescriber on the
 5 prescription label when prescribing mifepristone, misoprostol, gonado-
 6 tropin-releasing hormone agonists, pubertal suppressants, anabolic ster-
 7 oids, alpha reductase inhibitors, progestins, or drug classes for
 8 hormone replacement therapy for treatment of gender dysphoria.
 9 § 4. This act shall take effect immediately.

Go to top 

• 

 Sitemap 

 Request Information 

 Directions and Maps